文献速递创伤骨科关节外科骨质疏松与代谢性骨病

股骨颈骨折关节置换术后骨质疏松治疗与假体周围骨折风险的关联

The Association of Postoperative Osteoporosis Therapy With Periprosthetic Fracture Risk in Patients Undergoing Arthroplasty for Femoral Neck Fractures.
PubMed 文献 · J Arthroplasty · 2022-11-01

该研究基于国家数据库纳入2010至2020年因股骨颈骨折行髋关节置换的65岁以上患者,比较术后1年内启动抗骨质疏松治疗者与未治疗者的假体周围骨折风险。结果显示治疗组10年累积发生率3.88%,未治疗组5.92%(P < .001),校正协变量后治疗组假体周围骨折风险显著更低(HR 0.663;95%CI 0.465-0.861;P = .038)。作者认为骨质疏松治疗与较低的假体周围骨折发生率相关,并建议符合条件的股骨颈骨折患者启动骨质疏松治疗。

要点

  • 因股骨颈骨折行髋关节置换的65岁以上患者中,术后1年内启动抗骨质疏松治疗者2,026例,未治疗者33,639例。
  • 治疗组10年假体周围骨折累积发生率为3.88%,未治疗组为5.92%(P < .001)。
  • 校正协变量后,治疗组假体周围骨折风险显著低于未治疗组(HR 0.663;95%CI 0.465-0.861;P = .038)。

核心结论

  • 本研究提示,骨质疏松治疗与股骨颈骨折行髋关节置换术后较低的假体周围骨折发生率相关。
  • 作者认为,符合条件的股骨颈骨折患者应启动骨质疏松治疗,尤其是接受髋关节置换者。

研究设计与样本

  • 研究基于国家数据库识别2010至2020年因股骨颈骨折行髋关节置换、年龄至少65岁的患者。
  • 按髋关节置换术后1年内是否启动抗骨质疏松治疗分组,最短随访1年,最长随访10.6年。
  • 主要终点为假体周围骨折累积发生率,采用Kaplan-Meier分析和Cox比例风险回归分析。
  • 抗骨质疏松治疗组2,026例(平均随访4.8年;范围1.0至10.6年),未治疗组33,639例(平均随访4.1年;范围1.1至10.3年)。

主要发现

  • 治疗组10年假体周围骨折累积发生率为3.88%,未治疗组为5.92%(P < .001)。
  • 校正协变量后,治疗组假体周围骨折风险显著低于未治疗组(HR 0.663;95%CI 0.465-0.861;P = .038)。

临床怎么用

  • 作者认为,符合条件的股骨颈骨折患者应启动骨质疏松治疗,尤其是接受髋关节置换者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Displaced femoral neck fractures in older adults are generally treated with hip arthroplasty. One concern following hip arthroplasty is the risk for periprosthetic fractures (PPFs). Most patients who have hip fractures are candidates for antiosteoporotic therapy, but the impact of this treatment on PPFs is unknown. Therefore, the primary objective of this study was to evaluate whether patients treated with antiosteoporotic medical therapy had lower odds of PPFs following arthroplasty for hip fracture. METHODS: Patients at least 65 years old who underwent hip arthroplasty for femoral neck fractures from 2010 to 2020 were identified in a national database. Patients were stratified based on whether they initiated antiosteoporotic therapy within 1 year of hip arthroplasty. Minimum follow-up was 1 year, and maximum follow-up was 10.6 years. The primary endpoint was cumulative incidence of PPF as determined using Kaplan-Meier and Cox proportional hazards regression analyses. Overall, 2,026 patients who underwent arthroplasty for femoral neck fracture received antiosteoporotic medications within 1 year following surgery (mean follow up 4.8 years; range 1.0 to 10.6 years) and 33,639 patients did not (mean follow up 4.1 years; range 1.1 to 10.3 years). RESULTS: The 10-year cumulative incidence of PPF for patients treated for osteoporosis was 3.88% compared to 5.92% for those who were untreated (P < .001). Adjusting for covariates, patients who received osteoporosis treatment had a significantly lower risk for PPF than those who were untreated (hazard ratio (HR): 0.663; 95% confidence interval (CI): 0.465-0.861; P = .038). CONCLUSION: The present study suggests that osteoporosis treatment is associated with lower incidence of PPF following hip arthroplasty for femoral neck fractures. Treatment of osteoporosis should be initiated in eligible patients who sustain a femoral neck fracture, especially those who undergo hip arthroplasty.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Cohen JS, Agarwal AR, Kinnard MJ, et al. The Association of Postoperative Osteoporosis Therapy With Periprosthetic Fracture Risk in Patients Undergoing Arthroplasty for Femoral Neck Fractures. J Arthroplasty. 2022. PMID: 36328102. doi:10.1016/j.arth.2022.10.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。